SynthesisFrontiers in immunology2026
Long non-coding RNAs and their potential role in predicting immunotherapy response and prognosis: a systematic review.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, durable clinical benefit is limited to a subset of patients. Long non-coding RNAs (lncRNAs) have emerged as important regulators of tumor biology and immune responses and may serve as novel biomarkers to predict prognosis and response to ICIs. Methods: The systematic review was conducted according to PRISMA guidelines and registered in PROSPERO (CRD420251030158). Databases were searched from January 2010 to July 2025 for studies evaluating lncRNA expression in adult cancer patients treated with ICIs. Eligible studies assessed associations between lncRNAs expression and survival outcomes after ICI treatment. Results: After selection, 31 studies across multiple cancer types, were included. Most studies were retrospective bioinformatic analyses of public datasets and focused on ICI therapies. lncRNA-based signatures consistently demonstrated prognostic value by stratifying patients into groups with significantly different survival outcomes and were associated with variations in ICI response across multiple cancer types. Conclusions: LncRNAs represent promising prognostic and predictive biomarkers for ICI. Prospective validation and standardized analytical approaches are needed to support their clinical translation in precision immuno-oncology. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251030158.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.